https://www.nasdaq.com/press-release/agenus-to-participate-at-upcoming-investor-conferences-2022-01-05
https://www.nasdaq.com/press-release/balstilimab-plus-zalifrelimab-data-published-in-journal-of-clinical-oncology-jco-2021
https://www.nasdaq.com/press-release/agenus-to-participate-in-4th-annual-evercore-isi-healthconx-conference-2021-11-17
https://www.nasdaq.com/press-release/clinical-activity-of-agen1181-demonstrated-across-nine-treatment-resistant-cancers-at
https://www.nasdaq.com/press-release/agenus-to-participate-in-fireside-chat-at-the-b.-riley-fall-2021-growth-biotech-best
https://www.nasdaq.com/press-release/agenus-corporate-update-and-third-quarter-2021-financial-report-2021-11-09
https://www.nasdaq.com/press-release/agenus-to-participate-in-webcast-hosted-by-william-blair-to-discuss-agen1181-clinical
https://www.nasdaq.com/press-release/agenus-to-provide-corporate-update-and-third-quarter-2021-financial-report-2021-10-25
https://www.nasdaq.com/press-release/agenus-provides-update-on-balstilimab-development-2021-10-22
https://www.nasdaq.com/press-release/agenus-to-receive-%2420m-milestone-payment-from-bristol-myers-squibb-with-dosing-of
https://www.nasdaq.com/press-release/agenus-to-present-agen1181-clinical-data-at-sitc-2021-10-01
https://www.nasdaq.com/press-release/combination-of-balstilimab-plus-zalifrelimab-doubles-responses-in-2l-cervical-cancer
https://www.nasdaq.com/press-release/new-agenus-subsidiary-saponiqx-builds-innovative-adjuvant-platform-and-forms
https://www.nasdaq.com/press-release/agenus-to-participate-in-september-investor-conferences-2021-09-09
https://www.nasdaq.com/press-release/balstilimab-monotherapy-data-published-in-gynecologic-oncology-2021-08-26
https://www.nasdaq.com/press-release/agenus-corporate-update-and-second-quarter-2021-financial-report-2021-08-09
https://www.nasdaq.com/press-release/agenus-to-participate-in-the-btig-virtual-biotechnology-conference-2021-2021-08-02
https://www.nasdaq.com/press-release/mink-therapeutics-announces-confidential-submission-of-draft-registration-statement
https://www.nasdaq.com/press-release/agenus-to-provide-corporate-update-and-second-quarter-2021-financial-report-2021-07
https://www.nasdaq.com/press-release/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair
https://www.nasdaq.com/press-release/agenus-closes-%24200m-upfront-bms-collaboration-and-announces-fda-acceptance-of-ind-for
https://www.nasdaq.com/press-release/agenus-to-participate-in-the-raymond-james-2021-human-health-innovation-conference
https://www.nasdaq.com/press-release/agenus-announces-u.s.-fda-acceptance-and-priority-review-of-balstilimab-biologics
https://www.nasdaq.com/press-release/agenus-announces-virtual-annual-shareholders-meeting-2021-06-15
https://www.nasdaq.com/press-release/agenus-presentations-at-asco-2021-demonstrate-differentiated-activity-of-balstilimab
https://www.nasdaq.com/press-release/agenus-to-participate-in-fireside-chat-at-the-jefferies-2021-virtual-healthcare
https://www.nasdaq.com/press-release/agenus-presents-new-data-on-balstilimab-and-agen2373-in-asco-abstracts-2021-05-20
https://www.nasdaq.com/press-release/agenus-to-host-conference-call-to-discuss-global-licensing-agreement-with-bristol
https://www.nasdaq.com/press-release/agenus-and-bristol-myers-squibb-announce-exclusive-global-license-for-agenus-anti
https://www.nasdaq.com/press-release/agenus-and-bristol-myers-squibb-announce-exclusive-global-license-for-agenus-anti-0
https://www.nasdaq.com/press-release/agenus-corporate-update-and-first-quarter-2021-financial-report-2021-05-06
https://www.nasdaq.com/press-release/agenus-to-present-at-the-2021-asco-annual-meeting-2021-04-28
https://www.nasdaq.com/press-release/agenus-to-provide-corporate-update-and-first-quarter-2021-financial-report-2021-04-22
https://www.nasdaq.com/press-release/agenus-submits-balstilimab-biologics-license-application-to-the-u.s.-fda-for-patients
https://www.nasdaq.com/press-release/agenus-doses-first-cancer-patient-with-inkt-cell-therapy-2021-04-14
https://www.nasdaq.com/press-release/new-clinical-responses-for-agen1181-presented-at-aacr-2021-04-10
https://www.nasdaq.com/press-release/agenus-to-participate-in-webcast-hosted-by-william-blair-on-agen1181-and-balstilimab
https://www.nasdaq.com/press-release/agenus-corporate-update-and-fourth-quarter-full-year-2020-financial-report-2021-03-15
https://www.nasdaq.com/press-release/agenus-to-present-new-clinical-data-on-agen1181-at-aacr-2021-2021-03-10
https://www.nasdaq.com/press-release/agenus-to-provide-corporate-update-and-fourth-quarter-full-year-2020-financial-report
https://www.nasdaq.com/press-release/andy-hurley-named-agenus-chief-commercial-officer-2021-02-09
https://www.nasdaq.com/press-release/agenus-announces-agenus-insights-virtual-rd-miniseries-2021-02-09
https://www.nasdaq.com/press-release/agenus-announces-new-responses-for-agen1181-2021-02-09
https://www.nasdaq.com/press-release/agenus-announces-positive-preliminary-results-of-inkt-cell-therapy-trial-in-covid-19
https://www.nasdaq.com/press-release/agenus-enters-into-clinical-collaboration-with-nelum-for-zalifrelimab-combination
https://www.nasdaq.com/press-release/agenus-to-participate-in-b.-riley-securities-oncology-investor-conference-2021-01-19
https://www.nasdaq.com/press-release/completion-of-balstilimab-bla-filing-extended-to-1h2021-2020-12-03
https://www.nasdaq.com/press-release/agenus-launches-phase-2-trial-expansion-in-colon-cancer-for-agen1181-in-combination
https://www.nasdaq.com/press-release/agenus-to-participate-in-evercore-isi-3rd-annual-healthconx-conference-2020-11-25
https://www.nasdaq.com/press-release/agenus-to-participate-in-fireside-chat-at-the-jefferies-2020-virtual-london
https://www.nasdaq.com/press-release/agenus-and-dr.-steven-oday-to-participate-in-webcast-hosted-by-william-blair-on
https://www.nasdaq.com/press-release/agenus-and-dr.-steven-oday-to-participate-in-panels-at-the-virtual-sitc-2020-immuno
https://www.nasdaq.com/press-release/xoma-earns-first-milestone-payment-from-2018-royalty-purchase-agreement-2020-11-11
https://www.nasdaq.com/press-release/an-agenus-discovered-first-in-class-ilt4-antibody-mk-4830-enters-phase-2-2020-11-10
https://www.nasdaq.com/press-release/agenus-presents-additional-clinical-responses-and-novel-biomarker-data-at-sitc2020
https://www.nasdaq.com/press-release/dr.-steven-oday-named-agenus-chief-medical-officer-2020-11-05
https://www.nasdaq.com/press-release/agenus-doses-first-covid-19-patient-with-inkt-cell-therapy-2020-11-02
https://www.nasdaq.com/press-release/agenus-rd-update-third-quarter-financial-report-2020-10-29
https://www.nasdaq.com/press-release/agenus-to-report-third-quarter-earnings-2020-10-20
https://www.nasdaq.com/press-release/agenus-to-present-on-seven-novel-programs-at-sitc-2020-2020-10-14
https://www.nasdaq.com/press-release/susan-hirsch-joins-agenus-board-of-directors-2020-10-13
https://www.nasdaq.com/press-release/agenus-initiates-rolling-bla-submission-of-balstilimab-for-recurrent-metastatic
https://www.nasdaq.com/press-release/agenus-presents-results-from-two-large-cervical-cancer-trials-at-esmo-2020-09-18
https://www.nasdaq.com/press-release/dr.-jennifer-buell-speaks-live-at-scientific-american-inaugural-fireside-chat-series
https://www.nasdaq.com/press-release/agenus-to-participate-in-webcast-hosted-by-william-blair-on-esmo2020-results-and
https://www.nasdaq.com/press-release/paul-clark-joins-agenus-board-of-directors-2020-08-31
https://www.nasdaq.com/press-release/agenus-announces-esmo-oral-presentation-of-two-clinical-trials-of-balstilimab-alone
https://www.nasdaq.com/press-release/agenus-provides-rd-update-second-quarter-financial-report-2020-08-06
https://www.nasdaq.com/press-release/agenus-to-present-on-targeting-myeloid-cells-in-tumor-microenvironment-at-the-william
https://www.nasdaq.com/press-release/agenus-rd-update-second-quarter-earnings-report-2020-07-29
https://www.nasdaq.com/press-release/agenus-receives-%2435m-in-immuno-oncology-transaction-with-betta-pharmaceuticals-2020
https://www.nasdaq.com/press-release/agenus-to-participate-in-a-panel-on-cell-therapy-for-infectious-diseases-at-the-b.
https://www.nasdaq.com/press-release/agenus-cell-therapy-and-checkpoint-antibody-combinations-show-curative-preclinical
https://www.nasdaq.com/press-release/agenus-and-betta-pharmaceuticals-enter-into-a-license-agreement-for-balstilimab-and
https://www.nasdaq.com/press-release/agenus-and-agentus-to-participate-in-a-panel-presentation-on-cell-therapy-at-the
https://www.nasdaq.com/press-release/agenus-to-present-at-the-raymond-james-virtual-human-health-innovation-conference
https://www.nasdaq.com/press-release/agenus-announces-virtual-annual-shareholders-meeting-2020-06-16
https://www.nasdaq.com/press-release/fda-clears-ind-for-inkt-cells-to-treat-covid-19-patients-2020-06-02
https://www.nasdaq.com/press-release/asco-presentation-of-agenus-agen1181-by-dr.-steven-oday-2020-05-29
https://www.nasdaq.com/press-release/agenus-nextgen-ctla-4-antibody-agen1181-data-to-be-presented-at-asco-2020-05-14
https://www.nasdaq.com/press-release/fda-clears-agentus-ind-for-allogeneic-inkt-cell-therapy-2020-05-13
https://www.nasdaq.com/press-release/agenus-first-quarter-results-and-update-2020-05-07
https://www.nasdaq.com/press-release/agenus-to-report-first-quarter-2020-financial-results-on-may-7-2020-and-host
https://www.nasdaq.com/press-release/agenus-receives-fast-track-designation-for-balstilimab-in-advanced-cervical-cancer
https://www.nasdaq.com/press-release/agenus-receives-fast-track-designation-for-balstilimab-zalifrelimab-in-advanced
https://www.nasdaq.com/press-release/agenus-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/first-qs-21-royalty-payment-due-to-agenus-is-triggered-2020-03-10
https://www.nasdaq.com/press-release/agenus-to-report-fourth-quarter-and-full-year-2019-financial-results-on-march-12-2020
https://www.nasdaq.com/press-release/agenus-announces-positive-interim-data-from-balstilimab-and-zalifrelimab-clinical
https://www.nasdaq.com/press-release/agenus-announces-investor-day-on-february-20-2020-2020-02-06
https://www.nasdaq.com/press-release/agenus-commences-phase-1-trial-with-agen1223-2020-01-08
https://www.nasdaq.com/press-release/agenus-to-host-rd-day-november-15-2019-2019-11-12
https://www.nasdaq.com/press-release/agenus-receives-%2410m-from-urogen-pharma-for-rights-to-zalifrelimab-ctla-4-for
https://www.nasdaq.com/press-release/agenus-provides-corporate-update-with-third-quarter-2019-financial-results-2019-11-04
https://www.nasdaq.com/press-release/agenus-to-report-third-quarter-2019-financial-results-on-november-4-2019-and-host
https://www.nasdaq.com/press-release/agenus-to-present-at-the-2019-cantor-global-healthcare-conference-on-october-4-2019
https://www.nasdaq.com/press-release/agenus-milestone-triggers-%247.5m-payment-2019-08-08
https://www.nasdaq.com/press-release/agenus-reports-second-quarter-2019-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/agenus-to-report-second-quarter-2019-financial-results-on-august-8-2019-and-host
https://www.nasdaq.com/press-release/agenus-appoints-don-vidic-as-vice-president-and-head-of-commercial-2019-07-18
https://www.nasdaq.com/press-release/agenus-host-annual-meeting-stockholders-2019-06-13
https://www.nasdaq.com/press-release/mimedx-announces-comprehensive-board-refreshment-plan-cooperation-prescience-point
https://www.nasdaq.com/press-release/agenus-report-first-quarter-2019-financial-results-may-9-2019-and-host-conference
https://www.nasdaq.com/press-release/agenus-begins-dosing-next-gen-anti-ctla-4-antibody-2019-04-02
https://www.nasdaq.com/press-release/agenus-announces-clinical-appointments-2019-04-21
https://www.nasdaq.com/press-release/agenus-reports-fourth-quarter-and-full-year-2018-financial-results-and-provides
https://www.nasdaq.com/press-release/agenus-milestone-triggers-75m-payment-gilead-2019-04-21
https://www.nasdaq.com/press-release/agenus-report-fourth-quarter-and-full-year-2018-financial-results-march-14-2019-and
